Racial and Ethnic Disparities in Intensity of Care at the End of Life for Patients With Lung Cancer: A 13-Year Population-Based Study
CONCLUSION: Compared with NHW patients, API, Black, and Hispanic patients who died with lung cancer experienced higher intensity of EOL care. Future studies should develop approaches to eliminate such racial and ethnic disparities in care delivery at the EOL.PMID:38478794 | DOI:10.1200/JCO.23.01045 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Gladys M Rodriguez Rita Popat Lisa G Rosas Manali I Patel Source Type: research
Dietary intake of plant- and animal-derived protein and incident cardiovascular diseases: the pan-European EPIC-CVD case-cohort study
CONCLUSION: Plant- or animal-derived protein intake was not associated with overall CVD. However, the association of plant-derived protein consumption with lower total stroke incidence among non-smokers, and with lower incidence of fatal stroke highlights the importance of investigating CVD sub-types and potential interactions. These observations warrant further investigation in diverse populations with varying macronutrient intakes and dietary patterns.PMID:38479550 | DOI:10.1016/j.ajcnut.2024.03.006 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Ju-Sheng Zheng Marinka Steur Fumiaki Imamura Heinz Freisling Laura Johnson Yvonne T van der Schouw Tammy Y N Tong Elisabete Weiderpass Rashmita Bajracharya Marta Crous-Bou Christina C Dahm Alicia K Heath Daniel B Ibsen Franziska Jannasch Verena Katzke Gio Source Type: research
High-efficiency EGFR genotyping using cell-free DNA in bronchial washing fluid
CONCLUSIONS: Using supernatant of bronchial washing fluid samples, the detection rate of EGFR mutation was high, and EGFR mutations were detectable even when no tumor cells had been detectable by biopsy or cytology. Supernatant of bronchial washing fluid might be an effective sample source for EGFR mutation testing.PMID:38476004 | DOI:10.1093/jjco/hyae021 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Yoshihiko Murata Yumi Nakajima Yukio Sato Nobuyuki Hizawa Daichi Yamakawa Daisuke Matsubara Masayuki Noguchi Yuko Minami Source Type: research
Clinical predictors of response to single-agent immune checkpoint inhibitors in chemotherapy-pretreated non-small cell lung cancer
Mol Clin Oncol. 2024 Feb 20;20(4):32. doi: 10.3892/mco.2024.2730. eCollection 2024 Apr.ABSTRACTSingle-agent immune checkpoint inhibitors (ICIs) are the standard option for chemotherapy-pretreated metastatic non-small cell lung cancer (NSCLC), however only a subset of patients responds to this treatment. The present study aimed at the development of a tool for personalized prediction of the efficacy of ICIs. The study included 181 epidermal growth factor receptor/anaplastic lymphoma kinase-negative patients with metastatic NSCLC receiving single-agent ICI in the second or later line of therapy. For the comparison, a total o...
Source: Clinical Lung Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Aram A Musaelyan Fedor V Moiseyenko Tancholpon E Emileva Ani P Oganesyan Karina A Oganyan Magaripa A Urtenova Svetlana V Odintsova Ivan V Chistyakov Alexey M Degtyarev Andrey L Akopov Evgeny N Imyanitov Sergey V Orlov Source Type: research
Successful treatment of lung cancer coexisting with B-cell lymphoma with pembrolizumab following rituximab-included chemotherapy: A case report
In conclusion, the present study suggested that pembrolizumab, following rituximab-containing therapy, could be a treatment option for patients with lung cancer coexisting with MALT lymphoma.PMID:38476337 | PMC:PMC10928651 | DOI:10.3892/mco.2024.2731 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Daisuke Natori Hiroaki Ozasa Yusuke Shima Chisaki Mizumoto Keiichiro Suminaga Takashi Nomizo Hitomi Ajimizu Hironori Yoshida Toyohiro Hirai Source Type: research
In vitro PK/PD modeling of tyrosine kinase inhibitors in non-small cell lung cancer cell lines
Clin Transl Sci. 2024 Mar;17(3):e13714. doi: 10.1111/cts.13714.ABSTRACTTyrosine kinase inhibitors (TKIs) are routinely prescribed for the treatment of non-small cell lung cancer (NSCLC). As with all medications, patients can experience adverse events due to TKIs. Unfortunately, the relationship between many TKIs and the occurrence of certain adverse events remains unclear. There are limited in vivo studies which focus on TKIs and their effects on different regulation pathways. Many in vitro studies, however, that investigate the effects of TKIs observe additional changes, such as changes in gene activations or protein expr...
Source: Clinical Lung Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Linda Wanika Neil D Evans Martin Johnson Helen Tomkinson Michael J Chappell Source Type: research
Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes
Br J Clin Pharmacol. 2024 Mar 13. doi: 10.1111/bcp.16039. Online ahead of print.ABSTRACTWe sought to determine whether the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors is associated with a decreased risk of incident lung cancers among patients with type 2 diabetes. We assembled a new-user, active comparator cohort of SGLT-2 inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor users using the United Kingdom Clinical Practice Research Datalink. We fit Cox proportional hazards models with propensity score fine stratification weighting to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for incid...
Source: Clinical Lung Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Samantha B Shapiro Hui Yin Oriana H Y Yu Laurent Azoulay Source Type: research
Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of < em > FLT3 < /em >
CONCLUSION: Although the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.PMID:38471061 | DOI:10.1200/JCO.23.02474 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 12, 2024 Category: Cancer & Oncology Authors: Mark J Levis Mehdi Hamadani Brent Logan Richard J Jones Anurag K Singh Mark Litzow John R Wingard Esperanza B Papadopoulos Alexander E Perl Robert J Soiffer Celalettin Ustun Masumi Ueda Oshima Geoffrey L Uy Edmund K Waller Sumithra Vasu Melhem Solh Asmita Source Type: research
Pulmonary coccidioidomycosis mimicking malignancy associated with Sweet's syndrome (acute febrile neutrophilic dermatosis)
Clin Case Rep. 2024 Mar 7;12(3):e8651. doi: 10.1002/ccr3.8651. eCollection 2024 Mar.ABSTRACTA suspicious malignant lung nodule with cutaneous reaction is not always cancer, especially in low risk for malignancy patients. A lung biopsy should be taken into consideration. The associated cause of Sweet's syndrome directs the treatment in each patient.PMID:38464569 | PMC:PMC10920303 | DOI:10.1002/ccr3.8651 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 11, 2024 Category: Cancer & Oncology Authors: Nattanicha Chaisrimaneepan Austin Guadarrama Pitchaporn Yingchoncharoen Maria Batchinsky Source Type: research
Parotid metastasis of rare lung adenocarcinoma: A case report
CONCLUSION: This case report highlights the challenging diagnosis of parotid metastasis in LC given its rare nature. Such lesions should be differentiated from primary tumors of the parotid gland. Simple radiological imaging is unreliable, and puncture biopsy is needed for final diagnosis of this condition.PMID:38464919 | PMC:PMC10921301 | DOI:10.12998/wjcc.v12.i6.1182 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 11, 2024 Category: Cancer & Oncology Authors: Ru-Xi Yan Lin-Bo Dou Zi-Jia Wang Xue Qiao Hong-Hai Ji Yan-Cong Zhang Source Type: research
Current pharmacologic treatment of brain metastasis in non-small cell lung cancer
Clin Exp Metastasis. 2024 Mar 11. doi: 10.1007/s10585-024-10276-4. Online ahead of print.ABSTRACTLung cancer is a type of cancer that can metastasize to the lungs, brain, bones, liver, adrenal glands, and other organs; however, the occurrence of brain metastases is the most common event. Symptoms of brain metastasis include motor dysfunction, mental dysfunction, seizures, headaches, nausea, and vomiting, and significantly reduce the quality of life of cancer patients. Brain metastases are a poor prognostic factor, and controlling them is extremely important for prolonging prognosis and improving the quality of life. Curren...
Source: Clinical Lung Cancer - March 11, 2024 Category: Cancer & Oncology Authors: Takae Okuno Takeshi Isobe Yukari Tsubata Source Type: research
A pragmatic randomized clinical trial of multilevel interventions to improve adherence to lung cancer screening (The Larch Study): Study protocol
We describe the Larch Study protocol, which tests the effectiveness of two patient-centered interventions (Patient Voices Video and Stepped Reminders) designed to address barriers and improve annual LCS adherence.METHODS: The Larch Study is a pragmatic randomized clinical trial conducted within Kaiser Permanente Washington. Eligible patients (target n = 1606) are aged 50-78 years with an index low-dose CT (LDCT) of the chest with negative or benign findings. With a 2 × 2 factorial-design, patients are individually randomized to 1 of 4 arms: video only, reminders only, both video and reminders, or usual care. The Patient V...
Source: Clinical Lung Cancer - March 11, 2024 Category: Cancer & Oncology Authors: Casey Luce Lorella Palazzo Melissa L Anderson Lisa Carter-Bawa Hongyuan Gao Beverly B Green James D Ralston Kristine Rogers Yu-Ru Su Leah Tuzzio Matthew Triplette Karen J Wernli Source Type: research
Pulmonary coccidioidomycosis mimicking malignancy associated with Sweet's syndrome (acute febrile neutrophilic dermatosis)
Clin Case Rep. 2024 Mar 7;12(3):e8651. doi: 10.1002/ccr3.8651. eCollection 2024 Mar.ABSTRACTA suspicious malignant lung nodule with cutaneous reaction is not always cancer, especially in low risk for malignancy patients. A lung biopsy should be taken into consideration. The associated cause of Sweet's syndrome directs the treatment in each patient.PMID:38464569 | PMC:PMC10920303 | DOI:10.1002/ccr3.8651 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 11, 2024 Category: Cancer & Oncology Authors: Nattanicha Chaisrimaneepan Austin Guadarrama Pitchaporn Yingchoncharoen Maria Batchinsky Source Type: research
Parotid metastasis of rare lung adenocarcinoma: A case report
CONCLUSION: This case report highlights the challenging diagnosis of parotid metastasis in LC given its rare nature. Such lesions should be differentiated from primary tumors of the parotid gland. Simple radiological imaging is unreliable, and puncture biopsy is needed for final diagnosis of this condition.PMID:38464919 | PMC:PMC10921301 | DOI:10.12998/wjcc.v12.i6.1182 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 11, 2024 Category: Cancer & Oncology Authors: Ru-Xi Yan Lin-Bo Dou Zi-Jia Wang Xue Qiao Hong-Hai Ji Yan-Cong Zhang Source Type: research
Current pharmacologic treatment of brain metastasis in non-small cell lung cancer
Clin Exp Metastasis. 2024 Mar 11. doi: 10.1007/s10585-024-10276-4. Online ahead of print.ABSTRACTLung cancer is a type of cancer that can metastasize to the lungs, brain, bones, liver, adrenal glands, and other organs; however, the occurrence of brain metastases is the most common event. Symptoms of brain metastasis include motor dysfunction, mental dysfunction, seizures, headaches, nausea, and vomiting, and significantly reduce the quality of life of cancer patients. Brain metastases are a poor prognostic factor, and controlling them is extremely important for prolonging prognosis and improving the quality of life. Curren...
Source: Clinical Lung Cancer - March 11, 2024 Category: Cancer & Oncology Authors: Takae Okuno Takeshi Isobe Yukari Tsubata Source Type: research
